MarketBeat
13 Aug 2026, 05:02 UTC · 8w ago
Impact · against what's priced in
CSTL is showing strong fundamental momentum with a raised outlook and significant growth runway for TissueCypher. The potential for FDA clearance on the melanoma test provides a catalyst to reduce reimbursement friction, while the AdvanceAD-Tx test remains a long-term prospect for 2027.
No priced-in read yet
What the story claims
6 claims · scored −1 bearish … +1 bullish
Castle Biosciences raised its full-year outlook by an amount exceeding its second-quarter earnings beat.
So whatRaising guidance following a beat signals strong fundamental momentum and management confidence in second-half performance.
More positive than 93% of claims this week
TissueCypher has only 15% patient penetration, implying the business could more than double if it reaches levels similar to the melanoma test.
So whatSignificant untapped market share in a core product provides a clear path for substantial organic revenue growth.
Continue reading
5 related stories
The company raised its full-year outlook beyond its Q2 beat, driven by mid-to-high single-digit growth in melanoma tests and a TissueCypher penetration rate of only 15%, which suggests the product could more than double if it reaches melanoma-like adoption levels.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More positive than 87% of claims this week
The company expects to remain adjusted EBITDA positive through 2026 and into 2027.
So whatConfirmed profitability thresholds reduce financial risk and improve the company's valuation profile.
More positive than 79% of claims this week
Castle is seeking FDA clearance for its melanoma test to potentially strengthen reimbursement and prevent insurers from classifying it as experimental.
More positive than 67% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company reported continued momentum, raised its financial outlook, and demonstrated growth across its core diagnostic franchises.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
+4.2%
Price agrees with the score
$32.76 vs $31.43 close before publication (Aug 12) · not market-adjusted
CSTL chart →
